Treatment of undifferentiated thyroid carcinoma with darafini and trametinib:a case report and literature review

• 作者: Nan Nan Tao Chi Xiao-Juan Yan
• 来源期刊: TMR肿瘤
• 学科: 医学
• 关键词: UNDIFFERENTIATED THYROID carcinoma Darafini Trimetinib BRAFmutation
• 年，卷（期）: 2019,（3）
• 页码范围: 222-226
• 页数: 5页
• 分类号: R73

摘要

Undifferentiated thyroid carcinoma progresses rapidly and has a poor prognosis.The median progression-free survival is only about half a year,and the effect of conventional radiotherapy and chemotherapy is poor.Some patients may be associated with BRAF V600E mutation.Dabrafenib and trametinib were approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.The combination of the two may make patients receive a better benefit.A phase III clinical trial showed that in patients with advanced malignant melanoma with positive BRAF-V600E mutations,the combination of dabrafenib and trametinib can effectively improve progression-free survival and overall survival in patients.This article describes a case describing a patient with BRAF V600E-mutated thyroid undifferentiated carcinoma that was treated with darafini and trimetinib,and the relevant literature on the combination of the two drugs was analyzed.